Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Leo J Schep, Kai Knudsen, Robin J Slaughter, J Allister Vale & Bruno Mégarbane. (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clinical Toxicology 50:6, pages 458-470.
Read now
Read now
L.A.R. Stein, Rebecca Lebeau, Mary Clair, Rosemarie Martin, Monte Bryant & Susan Storti. (2012) Preliminary Web-Based Measures Development for GHB: Expectancies, Functions, and Withdrawal. The American Journal of Drug and Alcohol Abuse 38:2, pages 121-129.
Read now
Read now
I. B. Anderson, S. Y. Kim-Katz, J. E. Dyer & P. D. Blanc. (2010) The impact of gamma hydroxybutyrate (GHB) legal restrictions on patterns of use: Results from an International Survey. Drugs: Education, Prevention and Policy 17:5, pages 455-469.
Read now
Read now
J. G. O'Toole, M. R. Kristian, L. Devereux & R. Kurien. (2009) Gamma‐hydroxybutyrate dependence in a rural setting in Wales. Journal of Substance Use 14:1, pages 70-74.
Read now
Read now
Jane Carlisle Maxwell & Richard T. Spence. (2005) Profiles of Club Drug Users in Treatment. Substance Use & Misuse 40:9-10, pages 1409-1426.
Read now
Read now
Louisa Degenhardt, Jan Copeland & Paul Dillon. (2005) Recent Trends in the Use of “Club Drugs”: An Australian Review. Substance Use & Misuse 40:9-10, pages 1241-1256.
Read now
Read now
Jane Carlisle Maxwell. (2005) Party Drugs: Properties, Prevalence, Patterns, and Problems. Substance Use & Misuse 40:9-10, pages 1203-1240.
Read now
Read now
Gena Covell Britt & Elinore F. McCance-Katz. (2005) A Brief Overview of the Clinical Pharmacology of “Club Drugs”. Substance Use & Misuse 40:9-10, pages 1189-1201.
Read now
Read now
Alvaro Camacho, Scott C. Matthews, Brian Murray & Joel E. Dimsdale. (2005) Use of GHB Compounds Among College Students. The American Journal of Drug and Alcohol Abuse 31:4, pages 601-607.
Read now
Read now
RobertS. Gable. (2004) Acute Toxic Effects of Club Drugs. Journal of Psychoactive Drugs 36:3, pages 303-313.
Read now
Read now
. (2004) Comment on “The Abrupt Cessation of Therapeutically Administered Sodium Oxybate (GHB) May Cause Withdrawal Symptoms”. Journal of Toxicology: Clinical Toxicology 42:1, pages 121-123.
Read now
Read now
Gerald Chew & Antonio Fernando$suffix/text()$suffix/text(). (2004) Epileptic seizure in GHB withdrawal. Australasian Psychiatry 12:4, pages 410-411.
Read now
Read now
. (2003) The Abrupt Cessation of Therapeutically Administered Sodium Oxybate (GHB) Does Not Cause Withdrawal Symptoms. Journal of Toxicology: Clinical Toxicology 41:2, pages 131-135.
Read now
Read now
Karen Miotto, Jack Darakjian, Janice Basch, Shanna Murray, Jennifer Zogg, Richard Rawson, Karen Miotto, Jack Darakjian, Janice Basch, Shanna Murray, Jennifer Zogg & Richard Rawson. (2001) Gamma-Hydroxybutyric Acid: Patterns of Use, Effects and Withdrawal. American Journal on Addictions 10:3, pages 232-241.
Read now
Read now
Articles from other publishers (47)
Laurent Karila, Bernard Angerville, Amine Benyamina & Joël Billieux. (2024) Pharmacological Treatment of GHB Withdrawal Syndrome. Current Addiction Reports 11:1, pages 163-171.
Crossref
Crossref
Hans H. de Boer, Judith Fronczek & Melanie S. Archer. (2023) More on: ‘the role of restraint in fatal excited delirium syndrome’. Forensic Science, Medicine and Pathology.
Crossref
Crossref
Michael D. Freeman, Ellen M. F. Strömmer, Wendy M. Leith & Maurice P. Zeegers. (2023) Response to “Scrutinizing the causal link between excited delirium syndrome and restraint – a commentary on: ‘The role of restraint in fatal excited delirium: a research synthesis and pooled analysis’ by E.M.F. Strömmer, W. Leith, M.P. Zeegers and M.D. Freeman”. Forensic Science, Medicine and Pathology 19:4, pages 605-612.
Crossref
Crossref
Hans H. de Boer, Judith Fronczek & Melanie S. Archer. (2023) Scrutinizing the causal link between excited delirium syndrome and restraint: a commentary on ‘The role of restraint in fatal excited delirium: a research synthesis and pooled analysis’ by E.M.F. Strömmer, W. Leith, M.P. Zeegers, and M.D. Freeman. Forensic Science, Medicine and Pathology 19:4, pages 613-616.
Crossref
Crossref
Icro Maremmani, Matteo Pacini & Angelo G. I. MaremmaniIcro Maremmani, Matteo Pacini & Angelo G. I. Maremmani. 2023. Dual Disorder Heroin Addicts. Dual Disorder Heroin Addicts
183
195
.
Arianna Giorgetti, Francesco Paolo Busardò & Raffaele Giorgetti. (2022) Toxicological Characterization of GHB as a Performance-Enhancing Drug. Frontiers in Psychiatry 13.
Crossref
Crossref
Ellen M. F. Strömmer, Wendy Leith, Maurice P. Zeegers & Michael D. Freeman. (2020) The role of restraint in fatal excited delirium: a research synthesis and pooled analysis. Forensic Science, Medicine and Pathology 16:4, pages 680-692.
Crossref
Crossref
Sonia Habibian, Keith Ahamad, Mark McLean & Maria Eugenia Socias. (2019) Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report. Journal of Addiction Medicine 13:5, pages 415-417.
Crossref
Crossref
Harmen Beurmanjer, Rama M. Kamal, Cor A. J. de Jong, Boukje A. G. Dijkstra & Arnt F. A. Schellekens. (2018) Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. CNS Drugs 32:5, pages 437-442.
Crossref
Crossref
Christopher N. Floyd, David M. Wood & Paul I. Dargan. (2017) Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability. European Journal of Clinical Pharmacology 74:3, pages 349-356.
Crossref
Crossref
I. B. Zabolotskikh, N. V. Trembach, A. V. Butrov, E. S. Gorobets, E. V. Grigoriev, K. M. Lebedinsky, A. Yu. Lubnin, A. M. Ovezov, A. M. Ovechkin & A. V. Shchegolev. (2018) Perioperative management of patients with drug dependence. Anesteziologiya i Reanimatologiya:1-2, pages 133.
Crossref
Crossref
Douglas L. Blowey. 2018. Pediatric Hypertension. Pediatric Hypertension
617
627
.
. (2017) Treat γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence with benzodiazepines first, then with other approaches if benzodiazepine-resistant. Drugs & Therapy Perspectives 33:11, pages 523-528.
Crossref
Crossref
Rama M. Kamal, Martijn S. van Noorden, Wim Wannet, Harmen Beurmanjer, Boukje A. G. Dijkstra & Arnt Schellekens. (2016) Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. CNS Drugs 31:1, pages 51-64.
Crossref
Crossref
David M. Wood. 2017. Critical Care Toxicology. Critical Care Toxicology
1555
1586
.
Douglas L. Blowey. 2017. Pediatric Hypertension. Pediatric Hypertension
1
11
.
David M. Wood. 2016. Critical Care Toxicology. Critical Care Toxicology
1
32
.
John M. Corkery, Barbara Loi, Hugh Claridge, Christine Goodair, Ornella Corazza, Simon Elliott & Fabrizio Schifano. (2015) Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neuroscience & Biobehavioral Reviews 53, pages 52-78.
Crossref
Crossref
Jan van Amsterdam, Tibor Brunt, Ed Pennings & Wim van den Brink. (2014) Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regulatory Toxicology and Pharmacology 70:2, pages 507-513.
Crossref
Crossref
Christopher D Smith & Stefanie Robert. (2014) ‘Designer drugs’: update on the management of novel psychoactive substance misuse in the acute care setting. Clinical Medicine 14:4, pages 409-415.
Crossref
Crossref
LUCIO GHIO, ALICE CERVETTI, MATTEO RESPINO, MARTINO BELVEDERI MURRI & MARIO AMORE. (2014) Management and Treatment of Gamma Butyrolactone Withdrawal Syndrome. Journal of Psychiatric Practice 20:4, pages 294-300.
Crossref
Crossref
Donald G. Barceloux. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse
89
109
.
Samuel DeMariaJr.Jr.. 2012. Perioperative Addiction. Perioperative Addiction
111
128
.
H. Andresen, B. E. Aydin, A. Mueller & S. Iwersen‐Bergmann. (2011) An overview of gamma‐hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Testing and Analysis 3:9, pages 560-568.
Crossref
Crossref
David M. Wood, Alan D. Brailsford & Paul I. Dargan. (2011) Acute toxicity and withdrawal syndromes related to gamma‐hydroxybutyrate (GHB) and its analogues gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD). Drug Testing and Analysis 3:7-8, pages 417-425.
Crossref
Crossref
James Bell & Rodney Collins. (2010) Gamma‐butyrolactone (GBL) dependence and withdrawal. Addiction 106:2, pages 442-447.
Crossref
Crossref
Jørgen Bramness & Siren Haugland. (2011) Misbruk av gammahydroksybutyrat. Tidsskrift for Den norske legeforening 131:21, pages 2122-2125.
Crossref
Crossref
Janis M. Miyasaki. 2011. Hyperkinetic Movement Disorders. Hyperkinetic Movement Disorders
335
346
.
Laurent Karila, Johanne Novarin, Bruno Megarbane, Olivier Cottencin, Sylvain Dally, William Lowenstein & Michel Reynaud. (2009) Acide gamma-hydroxy-butyrique (GHB) : plus qu’un agent de soumission chimique, une véritable source d’addiction. La Presse Médicale 38:10, pages 1526-1538.
Crossref
Crossref
Lawrence P. Carter, Daniel Pardi, Jane Gorsline & Roland R. Griffiths. (2009) Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem®): Differences in characteristics and misuse. Drug and Alcohol Dependence 104:1-2, pages 1-10.
Crossref
Crossref
Lawrence P. Carter, Wouter Koek & Charles P. France. (2009) Behavioral analyses of GHB: Receptor mechanisms. Pharmacology & Therapeutics 121:1, pages 100-114.
Crossref
Crossref
E. O'shea. (2008) Éxtasis líquido: estudios neurobiológicos en el laboratorio. Trastornos Adictivos 10:3, pages 195-200.
Crossref
Crossref
Jeremy M. Wojtowicz, Mark C. Yarema & Paul M. Wax. (2015) Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 10:01, pages 69-74.
Crossref
Crossref
M. Isabel Colado, Esther O'Shea & A. Richard Green. 2007. Handbook of Contemporary Neuropharmacology. Handbook of Contemporary Neuropharmacology.
LAWRENCE S. QUANG. 2007. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose
803
823
.
LAWRENCE S. QUANG, GIANCARLO COLOMBO, CARLA LOBINA, PAOLA MACCIONI, ALESSANDRO ORRU`, GIAN LUIGI GESSA, TIMOTHY J. MAHER & MAURO A.M. CARAI. (2006) Evaluation for the Withdrawal Syndrome from γ‐Hydroxybutyric Acid (GHB), γ‐Butyrolactone (GBL), and 1,4‐Butanediol (1,4‐BD) in Different Rat Lines. Annals of the New York Academy of Sciences 1074:1, pages 545-558.
Crossref
Crossref
Eric Perez, Jason Chu & Theodore Bania. (2006) Seven Days of Gamma-Hydroxybutyrate (GHB) Use Produces Severe Withdrawal. Annals of Emergency Medicine 48:2, pages 219-220.
Crossref
Crossref
O. Carter SneadIIIIII & K. Michael Gibson. (2005) γ-Hydroxybutyric Acid. New England Journal of Medicine 352:26, pages 2721-2732.
Crossref
Crossref
Alejandro GonzalezDavid J. Nutt. (2016) Gamma hydroxy butyrate abuse and dependency. Journal of Psychopharmacology 19:2, pages 195-204.
Crossref
Crossref
Jaffar Alfardan & Michael J. Bennett. (2004) Lethargy, Failure to Thrive, and Psychomotor Retardation in an Infant. Laboratory Medicine 35:11, pages 665-668.
Crossref
Crossref
Ruth Garvey & Brian Fitzmaurice. (2014) Withdrawal delirium with dance drug ‘liquid ecstasy’ (GHB). Irish Journal of Psychological Medicine 21:2, pages 73-75.
Crossref
Crossref
Robert B Palmer. (2004) ??-Butyrolactone and 1,4-Butanediol. Toxicological Reviews 23:1, pages 21-31.
Crossref
Crossref
Jane Carlisle Maxwell. (2003) The response to club drug use. Current Opinion in Psychiatry 16:3, pages 279-289.
Crossref
Crossref
Jane Maxwell. (2003) Current Opinion in Psychiatry 16:3, pages 279-289.
Crossref
Crossref
Thomas E. Freese, Karen Miotto & Cathy J. Reback. (2002) The effects and consequences of selected club drugs. Journal of Substance Abuse Treatment 23:2, pages 151-156.
Crossref
Crossref
Phillip E. Mason & William P. KernsIIII. (2008) Gamma Hydroxybutyric Acid (GHB) Intoxication. Academic Emergency Medicine 9:7, pages 730-739.
Crossref
Crossref
Phillip E. Mason & William P. Kerns. (2002) Gamma Hydroxybutyric Acid (GHB) Intoxication. Academic Emergency Medicine 9:7, pages 730-739.
Crossref
Crossref